Literature DB >> 11221089

Relapse as histoid leprosy after receiving multidrug therapy (MDT); a report of three cases.

I N Shaw1, G Ebenezer, G S Rao, M M Natrajan, B Balasundaram.   

Abstract

The histoid type of leprosy has been described as occurring in lepromatous leprosy patients who relapse after many years of apparently successful dapsone monotherapy. Three patients who had received the World Health Organization-recommended regimens of multidrug therapy (WHO/MDT) relapsed as histoid leprosy 12-15 years after completion of treatment. In one patient, through mouse foot pad studies, the bacilli were found to be sensitive to rifampin and clofazimine and resistant to dapsone. In the other two patients mouse foot pad studies were inconclusive. The patients were re-started on WHO/MDT. Two patients took regular treatment and improved, both clinically and bacteriologically. One patient was irregular in treatment, and 1 year after re-starting WHO/MDT nodules were still present although the bacterial index had fallen slightly.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11221089

Source DB:  PubMed          Journal:  Int J Lepr Other Mycobact Dis        ISSN: 0148-916X


  3 in total

1.  Genotyping of Mycobacterium leprae from Brazilian leprosy patients suggests the occurrence of reinfection or of bacterial population shift during disease relapse.

Authors:  Adalgiza da Silva Rocha; Alexandre Araujo Cunha Dos Santos; Patrícia Pignataro; José Augusto Nery; Antônio Basílio de Miranda; Diego Fonseca Soares; Amanda Nogueira Brum Fontes; Alice Miranda; Helen Ferreira; Neio Boéchat; Maria Eugênia Novisck Gallo; Euzenir Nunes Sarno; Maria Leide W De Oliveira; Philip Noel Suffys
Journal:  J Med Microbiol       Date:  2011-05-19       Impact factor: 2.472

2.  De novo histoid leprosy in an elderly: a case report and review of the literature.

Authors:  Deepak Dimri; Bhawna Sethi; Yogesh Kumar
Journal:  Case Rep Pathol       Date:  2012-11-05

3.  De Novo Histoid Leprosy.

Authors:  Pooja Pandey; Mavinrkainahalli Srinivasa Murthy Suresh; Vivek Kumar Dey
Journal:  Indian J Dermatol       Date:  2015 Sep-Oct       Impact factor: 1.494

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.